Mersana Therapeutics Overview
- Founded
- 2001

- Status
- Public
- Employees
- 83

- Stock Symbol
- MRSN

- Share Price
- $19.78
- (As of Monday Closing)
Mersana Therapeutics General Information
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.
Contact Information
- 840 Memorial Drive
- Cambridge, MA 02139
- United States
Mersana Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$19.78 | $18.18 | $4.12 - $29.09 | $1.25B | 68.5M | 1.18M | -$1.34 |
Mersana Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 999,610 | 155,855 | 8,525 | 240,460 |
Revenue | 859 | 42,123 | 10,594 | 17,545 |
EBITDA | (74,917) | (28,955) | (64,398) | (38,689) |
Net Income | (75,449) | (28,208) | (64,257) | (38,707) |
Total Assets | 290,128 | 107,541 | 78,502 | 130,715 |
Total Debt | 16,830 | 7,764 | 0 | 0 |
Mersana Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.
Request a free trialMersana Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.
Request a free trialMersana Therapeutics Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMersana Therapeutics Competitors (41)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Turning Point Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
0000000 00000000 0 | Venture Capital-Backed | Beijing, China | 00000 | 00000000000 | 00000 | |
00000000 | Venture Capital-Backed | San Carlos, CA | 00 | 00000 | 00000000000 | 00000 |
000000000 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Mersana Therapeutics Executive Team (21)
Mersana Therapeutics Board Members (18)
Name | Representing | Role | Since |
---|---|---|---|
Andrew Hack Ph.D | Self | Board Member | 000 0000 |
Anna Protopapas | Mersana Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
David Mott | Self | Chairman & Board Member | 000 0000 |
Kristen Hege MD | Self | Board Member | 000 0000 |
Lawrence Alleva | Self | Board Member | 000 0000 |
Mersana Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMersana Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Mersana Therapeutics‘s full profile, request access.
Request a free trial